HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug trials for treatment of human angiostrongyliasis.

Abstract
Abdominal and cerebral angiostrongyliasis are two important infections produced by metastrongylid worms, the former occurring in Central and South America and the later in Asia and Pacific Islands. Drug treatment is a challenge since the worms and its evolving larvae live or migrate inside vessels and efficient killing of the parasites may produce more severe lesions. Larvicidal effect of certain drugs appears to be more easily accomplished but this outcome is not useful in abdominal angiostrongyliasis since clinical manifestations appear to result from sexual maturation of the worms. We review the drug trials in murine experimental models and conclude that most of them could not be considered good candidates for treatment of human infection, except for PF1022A, pyrantel and flubendazole.
AuthorsMárcia Bohrer Mentz, Carlos Graeff-Teixeira
JournalRevista do Instituto de Medicina Tropical de Sao Paulo (Rev Inst Med Trop Sao Paulo) 2003 Jul-Aug Vol. 45 Issue 4 Pg. 179-84 ISSN: 0036-4665 [Print] Brazil
PMID14502343 (Publication Type: Journal Article, Review)
Chemical References
  • Anthelmintics
Topics
  • Angiostrongylus (drug effects, growth & development)
  • Animals
  • Anthelmintics (therapeutic use)
  • Clinical Trials as Topic
  • Humans
  • Mice
  • Rats
  • Strongylida Infections (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: